The role of the NLRP3 inflammasome in gout

Sarah R Kingsbury1,2, Philip G Conaghan1,2, Michael F McDermott1,21Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UKAbstract: Gout is an inflammatory ar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarah R Kingsbury, Philip G Conaghan, Michael F McDermott
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/22efc42338034d50a014abc4ebba21f8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:22efc42338034d50a014abc4ebba21f8
record_format	dspace
spelling	oai:doaj.org-article:22efc42338034d50a014abc4ebba21f82021-12-02T01:38:02ZThe role of the NLRP3 inflammasome in gout1178-7031https://doaj.org/article/22efc42338034d50a014abc4ebba21f82011-03-01T00:00:00Zhttp://www.dovepress.com/the-role-of-the-nlrp3-inflammasome-in-gout-a6655https://doaj.org/toc/1178-7031Sarah R Kingsbury1,2, Philip G Conaghan1,2, Michael F McDermott1,21Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UKAbstract: Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint. Recent studies suggest that orchestration of the MSU-induced inflammatory response is dependent on the proinflammatory cytokine IL-1&szlig;, underlined by promising results in early IL-1 inhibitor trials in gout patients. This IL-1-dependent innate inflammatory phenotype, which is observed in a number of diseases in addition to gout, is now understood to rely on the formation of the macromolecular NLRP3 inflammasome complex in response to the MSU &#39;danger signal&#39;. This review focuses on our current understanding of the NLRP3 inflammasome and its critical role in MSU-crystal induced inflammatory gout attacks. It also discusses the management of treatment-resistant acute and chronic tophaceous gout with IL-1 inhibitors; early clinical studies of rilonacept (IL-1 Trap), canakinumab (monoclonal anti-IL-1&szlig; antibody), and anakinra have all demonstrated treatment efficacy in such patients.Keywords: gout, inflammasome, NLRP3, IL-1 Sarah R KingsburyPhilip G ConaghanMichael F McDermottDove Medical PressarticlePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol 2011, Iss default, Pp 39-49 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Sarah R Kingsbury Philip G Conaghan Michael F McDermott The role of the NLRP3 inflammasome in gout
description	Sarah R Kingsbury1,2, Philip G Conaghan1,2, Michael F McDermott1,21Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UKAbstract: Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint. Recent studies suggest that orchestration of the MSU-induced inflammatory response is dependent on the proinflammatory cytokine IL-1&szlig;, underlined by promising results in early IL-1 inhibitor trials in gout patients. This IL-1-dependent innate inflammatory phenotype, which is observed in a number of diseases in addition to gout, is now understood to rely on the formation of the macromolecular NLRP3 inflammasome complex in response to the MSU &#39;danger signal&#39;. This review focuses on our current understanding of the NLRP3 inflammasome and its critical role in MSU-crystal induced inflammatory gout attacks. It also discusses the management of treatment-resistant acute and chronic tophaceous gout with IL-1 inhibitors; early clinical studies of rilonacept (IL-1 Trap), canakinumab (monoclonal anti-IL-1&szlig; antibody), and anakinra have all demonstrated treatment efficacy in such patients.Keywords: gout, inflammasome, NLRP3, IL-1
format	article
author	Sarah R Kingsbury Philip G Conaghan Michael F McDermott
author_facet	Sarah R Kingsbury Philip G Conaghan Michael F McDermott
author_sort	Sarah R Kingsbury
title	The role of the NLRP3 inflammasome in gout
title_short	The role of the NLRP3 inflammasome in gout
title_full	The role of the NLRP3 inflammasome in gout
title_fullStr	The role of the NLRP3 inflammasome in gout
title_full_unstemmed	The role of the NLRP3 inflammasome in gout
title_sort	role of the nlrp3 inflammasome in gout
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/22efc42338034d50a014abc4ebba21f8
work_keys_str_mv	AT sarahrkingsbury theroleofthenlrp3inflammasomeingout AT philipgconaghan theroleofthenlrp3inflammasomeingout AT michaelfmcdermott theroleofthenlrp3inflammasomeingout AT sarahrkingsbury roleofthenlrp3inflammasomeingout AT philipgconaghan roleofthenlrp3inflammasomeingout AT michaelfmcdermott roleofthenlrp3inflammasomeingout
_version_	1718402944614793216

The role of the NLRP3 inflammasome in gout

Ejemplares similares